title: The role of p21Waf1/CIP1 as a Cip/Kip type cell-cycle  regulator in oral squamous cell carcinoma (Review).
abstract: Oral Squamous Cell Carcinoma (OSCC) is biologically characterized by the accumulation of multiple genetic and molecular alterations that end up clinically characterized as a malignant neoplasm through a phenomenon known as multistep. The members of the Cip/Kip family, specifically p21Waf1/CIP1, are responsible for cell cycle control, blocking the transition from phase G1 to phase S. We made a search of articles of peer-reviewed Journals in PubMed/ Medline, crossing the keywords. The goal of this paper is to determine the relationship between p21Waf1/CIP1 expression and several clinical and pathological aspects of OSCC, their relationship with p53 and HPV, as well as genetic alterations in their expression pattern, their use as a prognosis market in the evolution of precancerous lesions and their roles in anticancer treatments. The results of p21WAF1/CIP1 expression in OSCC showed mixed results in terms of positivity/negativity throughout different studies. It seems that, although p21Waf1/CIP1 expression is controlled in a p53-dependent manner, coexpression of both in OSCC is not intrinsically related. Although the presence of HPV viral oncoproteins increases p21Waf1/CIP1 levels, the small number of studies, have forced us to disregard the hypothesis that HPV infected lesions that present better prognosis are due to a p21Waf1/CIP1-dependent control. The role of p21WAF1/CIP1 as cell-cycle regulator has been well described; however, its relationship to OSCC, the clinical and pathological variables of tumors, HPV and different treatments are not entirely clear. Thus, it would be very interesting to pursue further study of this protein, which may have a significant value for the diagnosis, prognosis and therapy of this type of tumors.
authors: Oral Medicine, Oral Surgery and Implantology Unit, Institute of Research of Santiago de Compostela (IDIS), Faculty of Medicine and Dentistry, Santiago de Compostela, Spain. perezsayans@gmail.com
authors: Mario
authors: M
authors: Pérez-Sayáns
authors: José-Manuel
authors: JM
authors: Suárez-Peñaranda
authors: Pilar
authors: P
authors: Gayoso-Diz
authors: Francisco
authors: F
authors: Barros-Angueira
authors: José-Manuel
authors: JM
authors: Gándara-Rey
authors: Abel
authors: A
authors: García-García
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000235:genetics*; D002453:Cell Cycle; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics*; D009062:Mouth Neoplasms / Q000235:genetics*
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21
references: J Egypt Natl Canc Inst. 2009 Jun;21(2):85-92
references: 21057559
references: J Oral Pathol Med. 1998 Sep;27(8):376-81
references: 9736426
references: Anticancer Res. 2010 Jul;30(7):2799-803
references: 20683015
references: Pathol Res Pract. 1998;194(12):821-30
references: 9894247
references: J Oral Pathol Med. 2005 May;34(5):274-9
references: 15817070
references: Oral Oncol. 1998 May;34(3):198-203
references: 9692054
references: J Oral Pathol Med. 2008 Mar;37(3):151-6
references: 18251939
references: Anticancer Res. 2002 May-Jun;22(3):1445-51
references: 12168821
references: Anticancer Res. 2007 Mar-Apr;27(2):979-84
references: 17465230
references: J Appl Oral Sci. 2008 Sep-Oct;16(5):340-4
references: 19089231
references: Oral Oncol. 1998 Sep;34(5):353-60
references: 9861340
references: J Oral Maxillofac Surg. 2006 Nov;64(11):1617-23
references: 17052587
references: J Oral Pathol Med. 2002 Jan;31(1):16-22
references: 11896818
references: Arch Otolaryngol Head Neck Surg. 2002 Aug;128(8):897-902
references: 12162767
references: Int J Oral Maxillofac Surg. 2002 Apr;31(2):200-5
references: 12102420
references: Anticancer Res. 1998 Sep-Oct;18(5B):3645-50
references: 9854471
references: J Oral Pathol Med. 2000 Feb;29(2):56-62
references: 10718400
references: Oncol Rep. 1999 May-Jun;6(3):539-45
references: 10203588
references: Oral Oncol. 1999 Jan;35(1):63-9
references: 10211312
references: Cancer Lett. 1998 Nov 13;133(1):35-45
references: 9929158
references: Oncol Rep. 2007 Feb;17(2):355-9
references: 17203174
references: J Oral Pathol Med. 2007 Feb;36(2):88-92
references: 17238970
references: J Oral Pathol Med. 1998 Sep;27(8):367-75
references: 9736425
references: Oral Oncol. 1998 May;34(3):211-8
references: 9692056
references: J Oral Pathol Med. 2009 Jan;38(1):104-8
references: 19192055
references: Oncology. 2000 Jun;59(1):36-43
references: 10895065
references: Oral Oncol. 1999 May;35(3):333-42
references: 10621856
references: Oral Oncol. 2002 Jul;38(5):491-9
references: 12110345
references: Anticancer Res. 2004 Sep-Oct;24(5B):3225-31
references: 15510615
references: Auris Nasus Larynx. 2002 Apr;29(2):165-74
references: 11893452
references: Front Biosci. 2000 Apr 01;5:D406-23
references: 10762593
references: Cancer Res. 2005 Apr 15;65(8):3364-73
references: 15833870
references: Braz Dent J. 2004;15(2):93-8
references: 15776189
references: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Nov;94(5):593-600
references: 12424454
references: Anticancer Res. 2001 Jan-Feb;21(1B):521-8
references: 11299798
references: Oncol Rep. 2009 Dec;22(6):1277-82
references: 19885577
references: Clin Cancer Res. 2000 Jun;6(6):2440-7
references: 10873097
references: Int J Oncol. 2003 Feb;22(2):409-14
references: 12527941
references: Oral Oncol. 1998 Nov;34(6):529-37
references: 9930367